TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00436631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary management of seizures
Description: Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
Study: NCT04200664

Intervention type: DIAGNOSTIC_TEST
Intervention: Olfactory (smell) function testing
Description: Siderosis group participants will undergo a formal smell identification testing by means of self-administered smell chart to identify the revealed scents

Intervention type: GENETIC
Intervention: DNA bio-banking
Description: Siderosis group participants will be asked to provide a saliva sample for DNA bio-banking
Study: NCT05495516

Intervention type: GENETIC
Intervention: without Intervention
Description: without Intervention

Intervention type: GENETIC
Intervention: without Intervention
Description: without Intervention
Study: NCT03042039

Intervention type: OTHER
Intervention: New Care
Description: New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
Study: NCT03005925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: Smartphone application coupled with a hand dynamometer
Study: NCT02391298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Study: NCT02149186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCTuS-L
Study: NCT00476697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: German manufactured UVA1 emitting light system
Description: The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
Study: NCT04374721

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circadian gene expression evaluation
Description: patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circadian gene expression evaluation
Description: patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: circadian gene expression evaluation
Description: patients and controls will undergo circadian gene expression (CLOCK, ARNTL) evaluation at baseline and after 1, 3 and 6 months
Study: NCT00885430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pico-Salax
Description: Two sachets of Pico-Salax given 5 hours apart
Study: NCT04230590

Intervention type: OTHER
Intervention: Observational
Description: Participants will not receive any study intervention.~During the 24-week study period, participants will complete five assessment visits and passive digital data from participant's smartphone and study-provided wrist wearable device will be collected.
Study: NCT04371549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glue (Dermabond®; Ethicon, Somerville, NJ).
Description: Arm 1: Skin after cesarean section will be closed by glue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monocryl
Description: Arm 2: Skin after cesarean section will be closed by running subcuticular sutures using synthetic absorbable monofilament
Study: NCT00364832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration
Study: NCT01754337

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop system
Description: Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop system
Description: Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop system
Description: Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
Study: NCT02069483

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Feedback
Description: Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
Study: NCT03005925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical follow up
Description: regular visits with the specialist
Study: NCT01462773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
Study: NCT03122080

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture(EA)
Description: Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
Study: NCT00375830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: Scan to diagnose a number of bone conditions including cancer or metastasis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: Scan to diagnose a number of bone conditions including cancer or metastasis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone scan
Description: Scan to diagnose a number of bone conditions including cancer or metastasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-methyl diphosphonate
Description: Radiolabel for bone scan procedures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-methyl diphosphonate
Description: Radiolabel for bone scan procedures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-methyl diphosphonate
Description: Radiolabel for bone scan procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Description: Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Description: Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) scan
Description: Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fludeoxyglucose (18F-FDG)
Description: Radiolabel for positron emission tomography scan procedures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fludeoxyglucose (18F-FDG)
Description: Radiolabel for positron emission tomography scan procedures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fludeoxyglucose (18F-FDG)
Description: Radiolabel for positron emission tomography scan procedures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) scan
Description: Scan to detect \& analyze X-rays
Study: NCT00826475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction MBSR
Description: Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
Study: NCT00375830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT) scan
Description: Scan to detect \& analyze X-rays

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Sodium Fluoride (18F-NaF)
Description: Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Sodium Fluoride (18F-NaF)
Description: Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Sodium Fluoride (18F-NaF)
Description: Radiolabel for CT and PET scans, \& as a contrast agent for MRI scans.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
Description: Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.
Study: NCT01307085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning
Description: Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Study: NCT00375830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
Description: Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields \& radio waves to generate images of the organs in the body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine
Description: A gadolinium-based contrast agent for MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset
Description: A gadolinium-based contrast agent for MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset
Description: A gadolinium-based contrast agent for MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: A gadolinium-based contrast agent for MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: A gadolinium-based contrast agent for MRI
Study: NCT01675843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Description: The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
Study: NCT02789618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A01
Description: Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: B99
Description: Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: M89
Description: Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
Study: NCT02848794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Irinotecan
Description: Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
Study: NCT00364832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Differing doses and frequencies of sc administration
Study: NCT03186040

Intervention type: DRUG
Group type: OTHER
Intervention: Lacosamide
Description: Sodium channel blocker
Study: NCT02698566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
Study: NCT02513953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic
Description: Four Port Laparoscopic cystectomy
Study: NCT03031314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: barbed suture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard suture
Study: NCT02006719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: Treatment of Adhesive Capsulitis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study: NCT02801383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yallaferon®， the recombinant human interferon α-2b gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: gel without active ingredient
Study: NCT04115423

Intervention type: DRUG
Intervention: Tocilizumab
Description: A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.

Intervention type: DRUG
Intervention: Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)
Description: Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
Study: NCT01499316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Flow oxygen
Description: 10 minute shigh flow oxygen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Room Air
Description: Room air breathing
Study: NCT04699058

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-antibody test
Description: Questionnaire and COVID-antibody test for all participants

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-antibody test
Description: Questionnaire and COVID-antibody test for all participants
Study: NCT03562325

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy (ACT)
Description: The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
Study: NCT02412605

Intervention type: PROCEDURE
Intervention: Trophectoderm embryo biopsy
Description: Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred.

Intervention type: PROCEDURE
Intervention: Trophectoderm embryo biopsy
Description: Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred.
Study: NCT03566147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human primary Retinal Pigment Epithelial (HuRPE) cells
Description: HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human primary Retinal Pigment Epithelial (HuRPE) cells
Description: HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
Study: NCT02044822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg tablets administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously once weekly x 8 weeks
Study: NCT02528799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nexvax2
Description: Nexvax2 intra-dermal injections twice weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nexvax2
Description: Nexvax2 intra-dermal injections twice weekly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nexvax2
Description: Nexvax2 intra-dermal injections twice weekly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nexvax2 placebo
Description: Sodium chloride 0.9% intra-dermal injections twice weekly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nexvax2 placebo
Description: Sodium chloride 0.9% intra-dermal injections twice weekly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nexvax2 placebo
Description: Sodium chloride 0.9% intra-dermal injections twice weekly
Study: NCT02870244

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Escalating Doses
Description: Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10\^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10\^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10\^7/kg TIL 1383I TCR transduced T cells.